0001181431-13-040442.txt : 20130717
0001181431-13-040442.hdr.sgml : 20130717
20130717211002
ACCESSION NUMBER: 0001181431-13-040442
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20130717
FILED AS OF DATE: 20130717
DATE AS OF CHANGE: 20130717
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: OncoMed Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001302573
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 383572512
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 800 CHESAPEAKE DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
BUSINESS PHONE: 650-995-8200
MAIL ADDRESS:
STREET 1: 800 CHESAPEAKE DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GLAXOSMITHKLINE PLC
CENTRAL INDEX KEY: 0001131399
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35993
FILM NUMBER: 13973757
BUSINESS ADDRESS:
STREET 1: 980 GREAT WEST ROAD
CITY: BRENTFORD MIDDLESEX
STATE: X0
ZIP: TW8 9GS
BUSINESS PHONE: 011442080475000
MAIL ADDRESS:
STREET 1: 980 GREAT WEST ROAD
CITY: BRENTFORD MIDDLESEX
STATE: X0
ZIP: TW8 9GS
3
1
rrd385589.xml
X0206
3
2013-07-17
0
0001302573
OncoMed Pharmaceuticals Inc
OMED
0001131399
GLAXOSMITHKLINE PLC
980 GREAT WEST ROAD
BRENTFORD, MIDDLESEX
X0
TW8 9GS
UNITED KINGDOM
0
0
1
0
Series B-2 Preferred Stock
0
Class A Common Stock
1441396
I
By Corporation
Series B-3 Preferred Stock
0
Class A Common Stock
1166150
I
By Corporation
Each share of Series B-2 and Series B-3 Preferred Stock will automatically convert on a one-to-one basis into Common Stock immediately prior to the consummation of the Issuer's initial public offering.
The securities are immediately convertible.
The expiration date is not relevant to the conversion of these securities.
The Class A Common Stock will be redesignated "Common Stock" immediately prior to the consummation of the Issuer's initial public offering.
Shares of Preferred Stock are held of record by GlaxoSmithKline LLC, which is an indirect wholly-owned subsidiary of Reporting Person.
/s/ Simon Dingemans, Chief Financial Officer
2013-07-17